Revolutionizing Drug Delivery and Target Therapy with PEG-Conjugated Probes

Target Name: PEX1

NCBI ID: G5189

PEX1

Revolutionizing Drug Delivery and Target Therapy with PEG-Conjugated Probes

Peptide-conjugated probes (PEG-Pro) have emerged as a promising approach for drug delivery and targeting due to their ability to selectively target specific epitopes within the body. One of the growing areas of interest is the use of PEG-conjugated probes for drug discovery and development, particularly for the treatment of diseases caused by the overproduction or dysfunction of various proteins, including but not limited to cancer, neurodegenerative diseases, and autoimmune disorders.

PEG-conjugated probes, also known as Zn-PEG-Pro or ZWS (Zinc-PEG-Pro), are a type of PEG-conjugated protein that consists of a zinc ion linked to a protein or peptide sequence. ZNSs have been shown to have a superior stability and stability compared to other types of PEG-conjugated probes, such as classical PEG-Pros or G-PEG-Pros.

PEG-conjugated probes have been used in a wide range of applications, including cancer diagnosis and treatment. For example, ZNS-conjugated probes have been shown to be able to selectively target cancer cells, leading to a more precise and effective treatment. Additionally, ZNS-conjugated probes have been shown to have a lower potential for toxicity compared to other types of PEG-conjugated probes, making them a promising candidate for cancer treatment.

Furthermore, ZNS-conjugated probes have also been shown to be effective in delivering small molecules, such as drugs, toxins, or other therapeutic agents, to specific target sites within the body. This has the potential to revolutionize the field of drug delivery and target therapy, particularly for treatments that have limited systemic distribution or are difficult to deliver in humans.

PEG-conjugated probes have also been used in the development of novel diagnostic tools for diseases caused by the overproduction or dysfunction of various proteins. For example, ZNS-conjugated probes have been used to detect proteinuria in individuals with kidney disease, which is a common symptom of several types of cancer. Additionally, ZNS-conjugated probes have been shown to be effective in detecting proteinuria in individuals with liver cancer, which is a particularly aggressive form of cancer.

In conclusion, PEG-conjugated probes, including ZNS-conjugated probes, have the potential to revolutionize the field of drug delivery and target therapy for a wide range of diseases. By selectively targeting specific epitopes within the body and delivering small molecules to specific target sites , ZNS-conjugated probes have the potential to be a highly effective and safe treatment option for a variety of diseases. Further research is needed to explore the full potential of ZNS-conjugated probes and their potential as drug targets.

Protein Name: Peroxisomal Biogenesis Factor 1

Functions: Component of the PEX1-PEX6 AAA ATPase complex, a protein dislocase complex that mediates the ATP-dependent extraction of the PEX5 receptor from peroxisomal membranes, an essential step for PEX5 recycling (PubMed:11439091, PubMed:16314507, PubMed:16854980, PubMed:21362118, PubMed:29884772). Specifically recognizes PEX5 monoubiquitinated at 'Cys-11', and pulls it out of the peroxisome lumen through the PEX2-PEX10-PEX12 retrotranslocation channel (PubMed:29884772). Extraction by the PEX1-PEX6 AAA ATPase complex is accompanied by unfolding of the TPR repeats and release of bound cargo from PEX5 (PubMed:29884772)

The "PEX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets